Bone Mass Improvement after Tratment with Bisphosphonates in patients with Gaucher Disease Type 1 under irregular Enzyme Therapy

OLIVERI BEATRIZ; MASTAGLIA SILVINA ROSANA; DEGRANDI MC; FELIU A

Florianopolis - Brasil

Simposio; XI Symposium of Lysosomal Storage Disease; 2006

The cosen tratment for patients with Gaucher Disease Tipe 1 (GDI) is enzyme replacement therapy (ERT9) that sometimes is interrupted due to socioeconomic reasons. Around 80% of patients present bone involvement including osteopenia and asteoporosis. Biphosphonates are used in primary osteoporosis resulting in bone mineral density (BMD) increment and incidence of fractures decrease